Camille Desgrouas

Ms. Camille Desgrouas

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
CDCamille Desgrouas
Camille Desgrouas
NTNicolas Taudon
Nicolas Taudon
SBSok-siya Bun-Llopet
Sok-siya Bun-Llopet
BBBéatrice Baghdikian
Béatrice Baghdikian
SBSothavireak Bory
Sothavireak Bory
EOEvelyne Ollivier
Evelyne Ollivier

12 January 2024 in Cardiovascular Research
Verified
Journal Article
Closed access
PDF file
CDCamille Desgrouas
Camille Desgrouas
TTTabea Thalheim
Tabea Thalheim
MCMathieu Cerino
Mathieu Cerino
CBCatherine Badens
Catherine Badens
NBNathalie Bonello-Palot
Nathalie Bonello-Palot
The function of perilipin 1 in human metabolism was recently highlighted by the description of PLIN1 variants associated with various pathologies. These include severe familial partial lipodystrophy and early onset acute coronary syndrome. Additionally, certain variants have been reported to have a protective effect on cardiovascular diseases. The role of this protein remains controversial in mice and variant interpretation in humans is still conflicting. This literature review has two primary objectives (i) to clarify the function of the PLIN1 gene in lipid metabolism and atherosclerosis by examining functional studies performed in cells (adipocytes) and mice and (ii) to understand the impact of PLIN1 variants identified in humans based on the variant’s location within the protein and the type of variant (missense or frameshift). To achieve these objectives, we conducted an extensive analysis of the relevant literature on perilipin 1, its function in cellular models and mice, and the consequences of its mutations in humans. We also utilized bioinformatics tools and consulted the Human Genetics Cardiovascular Disease Knowledge Portal to enhance the pathogenicity assessment of PLIN1 missense variants.

25 April 2016 in Cells
Verified
Journal Article
Open access
PDF file
DGDamien Galant
Damien Galant
BGBénédicte GABORIT
Bénédicte GABORIT
CDCamille Desgrouas
Camille Desgrouas
IAInes Abdesselam
Ines Abdesselam
MBMonique Bernard
Monique Bernard
CBCatherine Badens
Catherine Badens
ZMPSTE24 encodes the only metalloprotease, which transforms prelamin into mature lamin A. Up to now, mutations in ZMPSTE24 have been linked to Restrictive Dermopathy (RD), Progeria or Mandibulo-Acral Dysplasia (MAD). We report here the phenotype of a patient referred for severe metabolic syndrome and cardiomyopathy, carrying a mutation in ZMPSTE24. The patient presented with a partial lipodystrophic syndrome associating hypertriglyceridemia, early onset type 2 diabetes, and android obesity with truncal and abdominal fat accumulation but without subcutaneous lipoatrophy. Other clinical features included acanthosis nigricans, liver steatosis, dilated cardiomyopathy, and high myocardial and hepatic triglycerides content. Mutated fibroblasts from the patient showed increased nuclear shape abnormalities and premature senescence as demonstrated by a decreased Population Doubling Level, an increased beta-galactosidase activity and a decreased BrdU incorporation rate. Reduced prelamin A expression by siRNA targeted toward LMNA transcripts resulted in decreased nuclear anomalies. We show here that a central obesity without subcutaneous lipoatrophy is associated with a laminopathy due to a heterozygous missense mutation in ZMPSTE24. Given the high prevalence of metabolic syndrome and android obesity in the general population, and in the absence of familial study, the causative link between mutation and phenotype cannot be formally established. Nevertheless, altered lamina architecture observed in mutated fibroblasts are responsible for premature cellular senescence and could contribute to the phenotype observed in this patient.

8 March 2012 in Malaria Journal
Verified
Journal Article
Open access
PDF file
CMCatherine Mullié
Catherine Mullié
AJAlexia Jonet
Alexia Jonet
CDCamille Desgrouas
Camille Desgrouas
NTNicolas Taudon
Nicolas Taudon
Pascal SonnetPascal Sonnet
Pascal Sonnet
A better anti-malarial efficiency and lower neurotoxicity have been reported for mefloquine (MQ) (+)- enantiomer. However, the importance of stereoselectivity remains poorly understood as the anti-malarial activity of pure enantiomer MQ analogues has never been described. Building on these observations, a series of enantiopure 4-aminoalcohol quinoline derivatives has previously been synthesized to optimize the efficiency and reduce possible adverse effects. Their in vitro activity on Plasmodium falciparum W2 and 3D7 strains is reported here along with their inhibition of β-haematin formation and peroxidative degradation of haemin, two possible mechanisms of action of anti-malarial drugs.

1 February 2014 in Separation and Purification Technology
Verified
Journal Article
Closed access
CDCamille Desgrouas
Camille Desgrouas
BBBéatrice Baghdikian
Béatrice Baghdikian
FMFathi Mabrouki
Fathi Mabrouki
SBSothavireak Bory
Sothavireak Bory
NTNicolas Taudon
Nicolas Taudon
EOEvelyne Ollivier
Evelyne Ollivier

1 July 2013 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
JDJérome Dormoi
Jérome Dormoi
SBSEBASTIEN BRIOLANT
SEBASTIEN BRIOLANT
CDCamille Desgrouas
Camille Desgrouas
BPBruno Pradines
Bruno Pradines
Although 100% of untreated mice infected with Plasmodium berghei died with specific signs of cerebral malaria and 100% of mice treated with 3 mg/kg dihydroartemisinin, the active metabolite of artesunate, which is used as the first-line treatment for severe malaria, also died but showed no specific signs of cerebral malaria, 78% of mice treated with 10 mg/kg Proveblue (methylene blue) and 78% of mice treated with a combination of 3 mg dihydroartemisinin and 10 mg/kg Proveblue survived and showed no specific signs of cerebral malaria or detectable parasites.